"Nicotinic Antagonists" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Drugs that bind to nicotinic cholinergic receptors (RECEPTORS, NICOTINIC) and block the actions of acetylcholine or cholinergic agonists. Nicotinic antagonists block synaptic transmission at autonomic ganglia, the skeletal neuromuscular junction, and at central nervous system nicotinic synapses.
| Descriptor ID |
D018733
|
| MeSH Number(s) |
D27.505.519.625.120.200.700 D27.505.696.577.120.200.700
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Nicotinic Antagonists".
Below are MeSH descriptors whose meaning is more specific than "Nicotinic Antagonists".
This graph shows the total number of publications written about "Nicotinic Antagonists" by people in this website by year, and whether "Nicotinic Antagonists" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2003 | 1 | 0 | 1 |
| 2007 | 1 | 1 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Nicotinic Antagonists" by people in Profiles.
-
Nicotinic receptors and lurasidone-mediated reversal of phencyclidine-induced deficit in novel object recognition. Behav Brain Res. 2016 Mar 15; 301:204-12.
-
ACSL6 is associated with the number of cigarettes smoked and its expression is altered by chronic nicotine exposure. PLoS One. 2011; 6(12):e28790.
-
Nicotine and cocaine self-administration using a multiple schedule of intravenous drug and sucrose reinforcement in rats. Behav Pharmacol. 2010 May; 21(3):182-93.
-
Targeting reward-relevant nicotinic receptors in the discovery of novel pharmacotherapeutic agents to treat tobacco dependence. Nebr Symp Motiv. 2009; 55:31-63.
-
The novel nicotinic receptor antagonist N,N'-dodecane-1,12-diyl-bis-3-picolinium dibromide decreases nicotine-induced dopamine metabolism in rat nucleus accumbens. Eur J Pharmacol. 2008 Dec 28; 601(1-3):103-5.
-
High affinity binding of epibatidine to serotonin type 3 receptors. J Biol Chem. 2008 Apr 11; 283(15):9659-65.
-
Bupropion inhibits the cellular effects of nicotine in the ventral tegmental area. Biochem Pharmacol. 2007 Oct 15; 74(8):1283-91.
-
Discovery of a novel nicotinic receptor antagonist for the treatment of nicotine addiction: 1-(3-Picolinium)-12-triethylammonium-dodecane dibromide (TMPD). Biochem Pharmacol. 2007 Oct 15; 74(8):1271-82.
-
The effects of a novel nicotinic receptor antagonist N,N-dodecane-1,12-diyl-bis-3-picolinium dibromide (bPiDDB) on acute and repeated nicotine-induced increases in extracellular dopamine in rat nucleus accumbens. Neuropharmacology. 2007 Mar; 52(3):755-63.
-
Effect of a novel nicotinic receptor antagonist, N,N'-dodecane-1,12-diyl-bis-3-picolinium dibromide, on nicotine self-administration and hyperactivity in rats. Psychopharmacology (Berl). 2006 Mar; 184(3-4):426-34.